Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

www.nature.com

Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

www.nature.com

paywallMB to

NatureEnglish · 10 days ago

Nature, Published online: 20 August 2025; doi:10.1038/s41586-025-09433-w

Dual cyclin A/B RxL inhibitors selectively kill small cell lung cancer cells and other cancer cells with high E2F activity.

From Nature via this RSS feed

You must log in or # to comment.

Chat

Nature

nature

You are not logged in. However you can subscribe from another Fediverse account, for example Lemmy or Mastodon. To do this, paste the following into the search field of your instance: !nature@ibbit.at

Community locked: only moderators can create posts. You can still comment on posts.

Nature is a weekly international journal publishing the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature also provides rapid, authoritative, insightful and arresting news and interpretation of topical and coming trends affecting science, scientists and the wider public.

Don’t post archive.is links or full text of articles, you will receive a temp ban.

Visibility: Public

This community can be federated to other instances and be posted/commented in by their users.

2 users / day
4 users / week
8 users / month
17 users / 6 months
1 local subscriber
9 subscribers
593 Posts
5 Comments
Modlog